Follicular Lymphoma | Clinical

June 12, 2022

The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies

June 08, 2022

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

June 04, 2022

Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.

May 31, 2022

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after receiving 2 or more lines of systemic therapy.

April 25, 2022

Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.

March 25, 2022

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

March 09, 2022

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

February 26, 2022

“It's an exciting time with all the novel agent development in relapsed indolent lymphoma,” according to Brad S. Kahl, MD.

January 18, 2022

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

December 13, 2021

The investigational agent glofitamab produced high responder rates in combination with obinutuzumab in multiple relapsed or refractory follicular lymphoma.